Purpose of this Study
Study visits at week 0, 4, 6, 8, and 12
Who Can Participate?
Eligibility
Participants with active AKC with symptoms of itching and eye redness
Age Range
18-65
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study wants to find out if an eye medicine called DFL24498 is safe and works well. People in the study will put one drop of the medicine in each eye four times a day for twelve weeks. Some people will get the real medicine, and others will get a liquid with no medicine in it, so the researchers can compare how well each one works.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Adult Participants with Atopic Keratoconjunctivitis (AKC) - TRAK
Principal Investigator
Amol
Sura
Protocol Number
PRO00119397
Phase
III
Enrollment Status
Pending Open to Enrollment